H.R. 8032: Facilitating Access to Innovation in Cancer Care Act
This bill, known as the Facilitating Access to Innovation in Cancer Care Act (or FAIC Act), aims to improve how certain cancer treatments are reimbursed under Medicare. The main focus is to ensure that some specified cancer treatments receive separate payments rather than being bundled into other service payments, which could potentially limit patient access to the necessary care.
Key Provisions of the Bill
- Separate Payment for Cancer Treatments: The bill specifies that from the year 2026 onwards, specific cancer treatments that meet particular cost criteria will receive separate payments by Medicare. This change will apply to treatments that have a mean per day product cost of $350 or more.
- Determining the Payment Amount: For qualifying cancer treatments, the payment amount will generally be the average sales price of that treatment. In cases where this information is not available, the payment will default to the wholesale acquisition cost or the mean unit cost based on hospital claims data.
- Adjustment for Budget Neutrality: To ensure that the total spending remains in line with existing budget constraints, necessary adjustments will be made to maintain budget neutrality regarding the expenditures under this new payment structure.
- Definition of Specified Cancer Treatment: The bill defines "specified cancer treatment" as any drug or biological approved by the FDA for cancer detection or treatment after January 1, 2008, that does not receive transitional pass-through payments and typically would be bundled with other outpatient covered services without this new provision.
Implementation Timeline
The provisions of this bill are set to take effect starting in the year 2026, meaning that health care providers and patients can expect these changes to be enacted and operational from that point forward.
Impact on Patients
By decoupling payment for certain cancer treatments from bundled services, the FAIC Act aims to improve access to innovative cancer therapies for Medicare beneficiaries. This could result in better treatment options and reduce financial barriers for patients in need of specific cancer therapies.
Regulatory Oversight
The Secretary of Health and Human Services will have the authority to implement these payment methodologies and ensure compliance with the changes outlined in the legislation, while also monitoring expenditures to keep them in line with budget expectations.
Relevant Companies
- NVS (Novartis AG): Novartis is a pharmaceutical company that develops cancer therapies; changes in reimbursement could impact their pricing strategies and market access for new treatments.
- PFE (Pfizer Inc.): Pfizer produces a range of cancer drugs, and the separate reimbursement structure could affect sales and how they market their products to healthcare providers.
- BMY (Bristol-Myers Squibb Company): This company also focuses on oncology treatments, which may see changes in the demand and reimbursement under Medicare due to this legislation.
This is an AI-generated summary of the bill text. There may be mistakes.
Sponsors
2 bill sponsors
Actions
2 actions
| Date | Action |
|---|---|
| Mar. 20, 2026 | Introduced in House |
| Mar. 20, 2026 | Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned. |
Corporate Lobbying
0 companies lobbying
None found.
* Note that there can be significant delays in lobbying disclosures, and our data may be incomplete.
